Drug intelligence / Profile preview

TG1024

Development stage: Unknown
Lead developer: Transgene
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies
Administration: Intratumoral

Overview

TG1024, also known as Ad-IL2, is a gene therapy product consisting of a genetically modified type 5 adenovirus encoding the human interleukin 2 (IL-2) gene. It is designed for intratumoral injection in patients with advanced solid tumors, including metastatic melanoma. The therapy aims to stimulate an anti-tumor immune response by delivering IL-2 directly into the tumor microenvironment via the adenoviral vector. Clinical development has focused on evaluating safety and determining optimal dosing regimens, including combination with chemotherapy agents such as dacarbazine. The drug was developed by Transgene.

Other names: Ad-IL2Ad-IL-2Ad-IL 2

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on TG1024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TG1024.

Explore the full profile